Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.
The initiative will begin with an executive roundtable, led by Diaceutics, focused on what is needed to unlock the full potential of diagnostic-driven therapies, so that more patients receive the treatments made for them.
Hosted and facilitated by Fierce Pharma, the roundtable will convene leaders and experts to explore key challenges, opportunities and priorities for progress, including what prevents patients from receiving the right treatment at the right time and how pharma, biotech, diagnostics, HCPs, laboratories and health systems could collaborate more effectively. Insights from the discussion will inform an in-depth report to be published this fall and help shape the program's ongoing industry engagement. Diaceutics published research shows that in advanced non-small cell lung cancer (aNSCLC), a disease where targeted therapy exists and should be benefiting patients, approximately 64% of eligible patients do not receive the appropriate targeted therapy. Roughly 29% are lost from the pathway even after a diagnostic test has successfully identified the actionable biomarker.
Recent research we conducted with senior commercial and medical leaders found strong agreement across company sizes, therapy areas and functions: the gap between what science makes possible and what happens in real-world care remains a significant and under-addressed industry challenge. While the momentum behind diagnostic-driven therapies is advancing rapidly, commercialization needs to catch up. Patients are still being missed between diagnosis and treatment. That's the gap we're focused on closing - and why we're working towards Precision for All. Closing the gap will require greater collaboration across the industry to make meaningful progress."
Jordan Clark, Chief Customer Officer, Diaceutics
Ryan Keeling, Diaceutics' CEO added: "We believe the benefits of what we call precision medicine today reach too few patients across too few diseases. In reality, the capability exists for us to address the majority of diseases in the same way by thinking more broadly about precision and how we approach diagnosis and treatment decision-making. We have the data, the tools and the engagement solutions that allow the industry to track patients in real time, identify and overcome known gaps and barriers, and find more eligible patients. It's not a pipe dream. We've built this, now it's about showing everybody what's possible when we put it to work.
That's why we're impatient to lead this discussion around the challenges and opportunities of commercializing diagnostic-driven therapies so that together, we can achieve a future where every eligible patient is found, diagnosed and receives the right therapy at the right time."
Built specifically around the commercialization needs of diagnostic-driven therapies, Diaceutics connects diagnostic insight, real-world data, scientific expertise, and targeted engagement to help biopharma teams see exactly where eligible patients are emerging, understand where action is needed, and engage the right HCPs at the right time.
Diaceutics defines diagnostic-driven therapies as therapies for which diagnostic activity influences whether, when, or how patients reach treatment. Diaceutics is currently equipped to support in the region of 700 therapies that require a diagnostic-driven approach. The need for this approach is expanding across a growing range of disease areas including renal, neurology, cardiovascular, metabolic, hematology and rare disease.